Skip to content
TrialScanner

NCT00626418

The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome

Phase 2CompletedLGNDLead

Registry record

Lead sponsor
Ligand Pharmaceuticals
Conditions
Restless Legs Syndrome
Primary completion
Oct 2008Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT00626418 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT00626418: The Effects of Aplindore on... | TrialScanner